Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b, Multi-Centre, Open-Label, Dose-Escalation and Dose-Expansion Study in Patients With Solid Tumour Malignancies to Evaluate GEH200520 Injection / GEH200521 (18F) Injection Safety and Tolerability, PET Imaging, Pharmacokinetics, and Changes in Imaging After Treatment

Next Previous
Trial Profile

A Phase 1a/1b, Multi-Centre, Open-Label, Dose-Escalation and Dose-Expansion Study in Patients With Solid Tumour Malignancies to Evaluate GEH200520 Injection / GEH200521 (18F) Injection Safety and Tolerability, PET Imaging, Pharmacokinetics, and Changes in Imaging After Treatment

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GEH-200520/GEH-200521 (Primary)
  • Indications Head and neck cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Diagnostic use; First in man

Most Recent Events

  • 19 Feb 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2026.
  • 19 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2026.
  • 25 Oct 2024 Results (n=8) presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top